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Several antitumor drugs have been described to possess antimicrobial effect. In this project we investigated the 
antimicrobial effect of rebeccamycin (which is still in phase II clinical trials in respect to antitumor activity), 
which have the ability to inhibit the catalytic action of topoisomerase I. Therefore, our proposal aims to identify 
the genetic markers present in the yeast Saccharomyces cerevisiae associated with resistance and sensibility to 
rebeccamycin analogs and to characterize their antimicrobial activity. In this line, BY4741 strain of S. cerevisiae
and the yeast Knock-out (YKO) deletion collection (Invitrogen) were divided into pools and inoculated at 30 °C 
in liquid YPD for 36 hours. Then, cells were diluted to OD600nm 0.2 in 96-well plate and exposed to 1mM 
rebeccamycin analogs for 4 hours. Using a replicator, pools were transferred to solid media and placed in an 
incubator at 30 °C for 72 hours and cell viability was evaluated by the ability to form colonies. After growth 
analysis of the wild type strain as well as the YKO deletion collection, the Reb analog that presented pronounced 
antimicrobial effect observed was Reb C, on pools 32 and 39 in relation to control and wild type strain. We 
observed that the minimum lethal dose of analog Reb C was around 1 mM, killing mutant pools 32 and 39. With 
this result we want to analyze the individual mutant growth from plates 32 and 39 from YKO in the established 
dose of analog Reb C, in order to identify possible molecular targets associated with resistance or sensibility to 
this drug. 
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Methicillin resistant Staphylococcus aureus (MRSA) is one of the major nosocomial pathogens. Biofilm 
formation is common in medical devices, such as catheters and prostheses, and allows the pathogen to resist to 
the host immune response and antimicrobials. To quantify the biofilm formation ability and to evaluate the in
vitro activity of different antimicrobial agents, alone or in combination, against prevalent MRSA SCCmec IV 
isolates from hospitals in Rio de Janeiro. The in vitro biofilm production ability was assessed for 43 clinical 
isolates, including 14 of sequence type (ST) 5, 9 ST1, 4 ST30 and 16 from other ST's, according to Stepanovic et 
al (2000). The biofilm susceptibility to gentamicin (Gen), linezolid (Lin), rifampicin (Rif) and vancomycin (Van) 
was determined for 6 isolates from three prevalent lineages (USA400/ST1, USA800/ST5, USA1100/ST30). 
After biofilm formation (24 h), the isolates were exposed to concentrations from 0.25 to 64g/mL of each 
antimicrobial agent, applied alone or in combination. Before and after antibiotic treatment, biofilms were 
characterized in terms of total biofilm mass (by crystal violet) and number of viable cells (CFU/cm2). The 
biofilm production was considered positive for 8 (57%) USA800/ST5 isolates (6 weak and 2 moderate), a single 
isolate USA400/ST1 was considered weak producer, and 2 USA1100/ST30 isolates were weak biofilm 
producers. After biofilm exposure to concentrations equal to or greater than 4 g/ml of Rif or Lin, a biomass 
reduction of 50 % was observed. For Gen or Van, it was verified a reduction of about 45 % but only after 
exposure to concentrations equal to or greater than 16g/mL. The synergism experiments showed improved 
biofilm mass reduction (55 %) using antimicrobials in concentrations lower than those mentioned above 
(Gen16g/mL + Rif2g/mL, Lin2g/mL + Rif2g/mL, Rif2g/mL + Van4g/mL, or Lin2g/mL + Van4g/mL). These latter results 
were equivalent to those obtained with high concentrations of the drugs used alone. Regarding biofilm cell 
viability, it was verified reductions of up to 1 log to Van64g/mL or Rif64g/mL, or 2 logs to Gen64g/mL or Lin64g/mL 
and between 2 and 3 logs in the synergisms of Lin2g/mL + Rif2g/mL, Rif2g/mL + Van4g/mL or Gen16g/mL + Rif2g/mL). 
Data demonstrated that antibiotic synergisms involving Lin2g/mL + Rif2g/mL and Rif2g/mL + Van4g/mL appear to be 
good therapy choices, since both produced greater reductions in biomass and number of cells in staphylococcal 
biofilms. 
 
II International Conference on Antimicrobial Research - ICAR2012 
              Lisbon (Portugal) 21-23 November 2012
408
